Preferred Label : Vandortuzumab Vedotin;
NCIt synonyms : Thio-anti-STEAP1-MC-vc-PAB-MMAE;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated,
via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin
derivative and a potent microtubule disrupting agent, with potential antineoplastic
activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety
of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized,
thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which
then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest
and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed
in a variety of cancer cell types.;
UNII : 44OUQ00D1U;
CAS number : 1471985-92-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1471985-92-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : RG7450; DSTP3086S; MSTP2109A;
NCI Metathesaurus CUI : CL433770;
Origin ID : C116748;
UMLS CUI : C4053881;
Semantic type(s)
- concept_is_in_subset
- has_target
